Literature DB >> 9720765

Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors.

N Saldou1, R Obernolte, A Huber, P A Baecker, R Wilhelm, R Alvarez, B Li, L Xia, O Callan, C Su, K Jarnagin, E R Shelton.   

Abstract

Four cyclic-nucleotide phosphodiesterase (PDE) genes belonging to the PDE4 family (PDE4A, 4B, 4C and 4D) have been identified. All four isogenes, including several deletions and alterations of the amino, carboxyl and central catalytic domains, were expressed in insect cells. Lysates were characterised for enzyme activity by using the Km for substrate and the EC50 for activation by the cofactor Mg2+. The catalytic domain alone appears to be sufficient for the normal enzymatic function of PDE4 proteins. Substrate affinity varied by less than 2-fold between catalytic-domain forms of the PDE4A, 4B and 4D isogenes and the long forms (PDE4A5, PDE4B1 and PDE4D3). The affinity for Mg2+ varied by less than 4-fold between long and catalytic-domain forms of PDE4A and 4B. The catalytic-domain form of PDE4D, however, had a 12-fold lower affinity for Mg2+ that was restored by including a portion of the amino-terminal domain, upstream conserved region-2 (UCR2). This result suggests that the Mg2+-binding site of PDE4D involves the UCR2 region. Inhibition of the PDE4 proteins by synthetic compounds is apparently affected differently by the domains. For PDE4B, the catalytic domain is sufficient for interactions with the inhibitors studied: IBMX, trequinsin, rolipram, TVX 2706, RP 73401 and RS-25344. For PDE4D the catalytic-domain form is less sensitive than the long form to inhibition by RS-25344, rolipram and TVX 2706, by 1463-, 11-and 12-fold, respectively. Addition of UCR2 to the catalytic-domain form of PDE4D restored all the lost sensitivities. The catalytic-domain form of PDE4A showed a reduced inhibitor affinity with RS-25344 and TVX 2706 by 77- and 90-fold, respectively. Both catalytic-domain and long forms of PDE4 isogenes interacted with equal affinity with the non-specific inhibitors IBMX and trequinsin, as well as the very potent PDE4-specific inhibitor RP 73401. Other potent and specific PDE4 inhibitors, such as rolipram, RS-25344 or TVX 2706, appear to utilize non-catalytic domain interactions with PDE4D and 4A to supplement those within the catalytic domains. These observations suggest a different relation between amino and catalytic domains in PDE4D relative to PDE4B. We therefore propose a model to illustrate these isogene-specific PDE4 domain interactions with substrate, inhibitors and the co-factor Mg2+. The model for PDE4D is also discussed in relation to changes in the activation curve for Mg2+ and sensitivity to RS-25344 that accompany phosphorylation of the long form by protein kinase A.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9720765     DOI: 10.1016/s0898-6568(97)00169-1

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  12 in total

1.  Inhibition of type 4 cAMP-phosphodiesterases (PDE4s) in mice induces hypothermia via effects on behavioral and central autonomous thermoregulation.

Authors:  Will McDonough; Justin Rich; Ileana V Aragon; Lina Abou Saleh; Abigail Boyd; Aris Richter; Anna Koloteva; Wito Richter
Journal:  Biochem Pharmacol       Date:  2020-07-20       Impact factor: 5.858

2.  Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4.

Authors:  Peder Cedervall; Ann Aulabaugh; Kieran F Geoghegan; Thomas J McLellan; Jayvardhan Pandit
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-09       Impact factor: 11.205

Review 3.  Targeting adenosine in cancer immunotherapy: a review of recent progress.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Anticancer Ther       Date:  2017-04-27       Impact factor: 4.512

4.  Computational investigation of the dynamic control of cAMP signaling by PDE4 isoform types.

Authors:  Dean Paes; Sammy Hermans; Daniel van den Hove; Tim Vanmierlo; Jos Prickaerts; Aurélie Carlier
Journal:  Biophys J       Date:  2022-06-18       Impact factor: 3.699

5.  Identification of compounds that potentiate CREB signaling as possible enhancers of long-term memory.

Authors:  Menghang Xia; Ruili Huang; Vicky Guo; Noel Southall; Ming-Hsuang Cho; James Inglese; Christopher P Austin; Marshall Nirenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

6.  Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.

Authors:  Alex B Burgin; Olafur T Magnusson; Jasbir Singh; Pam Witte; Bart L Staker; Jon M Bjornsson; Margret Thorsteinsdottir; Sigrun Hrafnsdottir; Timothy Hagen; Alex S Kiselyov; Lance J Stewart; Mark E Gurney
Journal:  Nat Biotechnol       Date:  2009-12-27       Impact factor: 54.908

7.  Inhibition of cAMP-phosphodiesterase 4 (PDE4) potentiates the anesthetic effects of Isoflurane in mice.

Authors:  Ileana V Aragon; Abigail Boyd; Lina Abou Saleh; Justin Rich; Will McDonough; Anna Koloteva; Wito Richter
Journal:  Biochem Pharmacol       Date:  2021-02-18       Impact factor: 5.858

8.  The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.

Authors:  Sandra Marie Schaal; Maneesh Sen Garg; Mousumi Ghosh; Lilie Lovera; Michael Lopez; Monal Patel; Jack Louro; Samik Patel; Luis Tuesta; Wai-Man Chan; Damien Daniel Pearse
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

9.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

10.  Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target.

Authors:  Thavy Long; Liliana Rojo-Arreola; Da Shi; Nelly El-Sakkary; Kurt Jarnagin; Fernando Rock; Maliwan Meewan; Alberto A Rascón; Lin Lin; Katherine A Cunningham; George A Lemieux; Larissa Podust; Ruben Abagyan; Kaveh Ashrafi; James H McKerrow; Conor R Caffrey
Journal:  PLoS Negl Trop Dis       Date:  2017-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.